Status:
UNKNOWN
Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness
Lead Sponsor:
McGill University
Conditions:
Breathlessness
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
Breathlessness on exertion is a common and troublesome complaint of individuals with restrictive lung disorders. In these adults, breathlessness contributes to physical activity-limitation and avoidan...
Eligibility Criteria
Inclusion
- Male
- Aged 18-40 years
- FEV1 ≥80% predicted
- FEV1/FVC \>70%
Exclusion
- Current or ex-smoker
- Body Mass Index \<18.5 or \>30 kg/m2
- Self-reported history of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
- Taking doctor prescribed medications
- Allergy to sulfa medications
Key Trial Info
Start Date :
April 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01851980
Start Date
April 1 2016
End Date
September 1 2017
Last Update
February 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre of Innovative Medicine of the McGill University Health Centre
Montreal, Quebec, Canada, H4A 3J1